Perseus Proteomics (4882) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Although losses continued as is typical for a drug discovery company pursuing a research and development-led strategy, the operating deficit narrowed due to higher revenue and cost control. Revenue was ¥1.03B (+24.1% YoY), operating income was ¥-5.73B (¥-6.30B in the previous year), ordinary income was ¥-5.09B (¥-6.24B in the previous year), and net income was ¥-5.47B (¥-6.94B in the previous year). The structure in which selling, general and administrative expenses, including ¥4.45B in R&D expenses, substantially exceed the scale of revenue remains unchanged, while subsidy income of ¥0.53B provided support for ordinary income.

Factors Affecting Performance

【Revenue】Revenue increased 24.1% YoY to ¥1.03B. Gross profit also increased 23.2% YoY to ¥0.90B, while the gross margin remained broadly flat at a high level of 87.8% (88.5% in the previous year). Although segment information is not disclosed, the absolute scale of revenue remains small and limited relative to R&D expenses of ¥4.45B.

【Profit and Loss】The operating loss was ¥5.73B, narrowing by ¥0.57B from ¥6.30B in the previous year. SG&A expenses decreased by approximately 5.6% YoY to ¥6.64B, while R&D expenses declined only slightly to ¥4.45B, indicating that cost discipline was effective. Non-operating income of ¥0.66B, including ¥0.53B in subsidy income and ¥0.09B in foreign exchange gains, reduced the ordinary loss by ¥0.64B relative to the operating loss, resulting in an ordinary loss of ¥5.09B. An impairment loss of ¥0.37B (¥0.68B in the previous year) was recorded as an extraordinary loss, resulting in a net loss of ¥5.47B (¥6.94B in the previous year). This represents a phase of higher revenue and reduced losses, with the decline in losses attributable to revenue growth; within the framework of higher revenue with higher or lower earnings, it corresponds to “loss reduction due to higher revenue.”

Key Financial Indicators

【Profitability】The operating margin was -556.3% (-759.0% in the previous year), while the net profit margin was -531.1% (-836.1% in the previous year). Although the magnitude of the losses narrowed in both cases, they remain substantially negative. The gross margin was high at 87.8%, but R&D expenses reached 431.6% of revenue, meaning that development investment continues to have a major influence on profitability.【Cash Flow Quality】Subsidy income of ¥0.53B was included in non-operating income, indicating that non-recurring factors contributed to the improvement in ordinary income.【Investment Efficiency】Annualized ROE was -82.5%, and the total asset turnover ratio was low at 0.104x. The recognition of net losses and the small scale of revenue relative to total assets are weighing on capital efficiency.【Financial Soundness】The equity ratio was 66.9%, down from 74.4% in the previous year, while the current ratio was approximately 1,290%, indicating exceptionally strong short-term liquidity. However, net assets decreased by ¥5.48B to ¥8.84B from ¥14.32B in the previous year, making the evolution of capital resources amid continued losses a key issue.

Cash Flow Analysis

Because individual figures from the cash flow statement have not been disclosed, cash trends are analyzed based on changes in the balance sheet. Cash and deposits were ¥12.36B, down ¥4.32B (-25.9%) from ¥16.68B in the same period of the previous year. The decline in cash amid a continuing net loss of ¥5.47B is believed to have been primarily attributable to cash consumption associated with R&D investment. Although the current ratio of approximately 1,290% provides substantial short-term funding flexibility, total assets also declined by ¥4.96B YoY. The balance between the pace of losses and cash holdings will therefore be a key area to monitor over the medium term.

Quality of Earnings

Non-recurring factors contributed to the improvement in ordinary income and must be distinguished when evaluating earnings quality. Subsidy income of ¥0.53B, which accounted for most of the ¥0.66B in non-operating income, is an item for which recurrence cannot readily be assumed in the same manner as revenue. Excluding this item, underlying operating profitability remains challenging. The ¥0.37B impairment loss (¥0.68B in the previous year) recorded as an extraordinary loss was a temporary factor that reduced final earnings, and a corresponding portion of the ¥5.47B net loss was attributable to non-recurring items. Retained earnings improved substantially to ¥-5.48B from ¥-38.09B in the previous year. However, this was accompanied by significant changes in share capital and capital surplus, and it should be noted that the improvement may reflect a reorganization of the capital structure, such as the elimination of accumulated deficits, rather than an improvement in profitability from operating activities.

Shareholder Returns

Both the Q2 dividend and the full-year dividend forecast were ¥0 per share, resulting in an effective payout ratio of 0%. As no share repurchases have been confirmed, the total return ratio is not evaluated. Given the continued recognition of net losses and the need for R&D investment, the capital allocation policy appears to prioritize maintaining liquidity and continuing development investment over shareholder returns.

Risk Factors

1. Development-led earnings structure risk: R&D expenses of ¥4.45B reached 431.6% of revenue. If commercialization of development outcomes is delayed, the operating deficit could persist for an extended period.

2. Capital depletion risk: The net loss of ¥5.47B and annualized ROE of -82.5% continue, while net assets decreased by ¥5.48B YoY to ¥8.84B. The equity ratio also declined from 74.4% to 66.9%, making the potential erosion of capital resources under continued losses a key issue.

3. Dependence on non-recurring income risk: Part of the improvement in ordinary income depended on subsidy income of ¥0.53B, for which recurrence comparable to ordinary revenue cannot readily be expected. In addition, an impairment loss of ¥0.37B was recorded, requiring continued monitoring of asset valuations.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (pharma)

Profitability and Returns

Although many companies in the industry are loss-making, the company’s loss margin is substantially wider than the median, representing an unfavorable position.

Growth and Capital Efficiency

The revenue growth rate is substantially above the industry median, indicating relatively strong top-line growth.

Source: Compiled by the Company

Key Takeaways from the Financial Results

1. Revenue increased 24.1% YoY, and the operating loss narrowed by ¥0.57B. The improvement was accompanied by SG&A expense controls, indicating that cost discipline contributed to the reduction in losses.

2. The operating margin of -556.3% and net profit margin of -531.1% are substantially below the industry medians, indicating that monetization remains some time away. The primary reason is the structure in which R&D expenses account for 431.6% of revenue.

3. Subsidy income of ¥0.53B contributed to the reduction in the ordinary loss, and this should be assessed separately from underlying operating profitability. Cash and deposits decreased by ¥4.32B YoY, making the pace of cash consumption a key area of focus going forward.

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional as necessary.

---End of Report---